TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company†or "Organigram†), Canada's #1 cannabis company by market share1, today announced the expansion of its innovation investment in Phylos Bioscience Inc. ("Phylos†), securing Organigram's position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos' autoflower genetics pipeline, including preferential economic terms and long-ter. ...

Core Viewpoint - Organigram Global Inc. (OGI) has shown robust growth and operating leverage, leading to margin expansion, which justifies a buy rating initiated last August. The stock has increased by 31% since the rating due to solid Q4 performance [1]. Company Analysis - The company has demonstrated strong growth metrics, contributing to a favorable investment outlook. The increase in stock price reflects positive market sentiment and operational efficiency [1]. Market Trends - The analysis highlights the importance of thorough research and understanding of financial statements and market trends, which are critical for identifying undervalued investment opportunities in mid and small-cap companies [1].

Core Insights - Organigram Holdings Inc. is a significant player in the Canadian cannabis industry, focusing on recreational cannabis products [1] - Alliance Global Partners has a "Buy" rating for Organigram, raising the price target from C$3.60 to C$4, reflecting confidence in the company's future performance [1][5] Financial Performance - Organigram reported a quarterly loss of C$(0.283) per share, which is significantly below the Zacks Consensus Estimate and represents a substantial increase from the $0.04 loss per share reported in the same quarter last year [2][5] - The company's revenue for the quarter ending September 2025 was C$80.1 million, exceeding the Zacks Consensus Estimate by 7.1%, indicating strong sales growth despite earnings challenges [3][5] Stock Performance - Organigram's stock is currently priced at $1.93, reflecting a positive change of 7.5% or an increase of $0.135, with a trading volume of 3,754,420 shares [4] - The stock has fluctuated between a low of $1.70 and a high of $1.98 during the day, and over the past year, it has reached a high of $2.07 and a low of $0.85 [4]

OrganiGram (OGI) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1,900.00%. A quarter ago, it was expected that this cannabis producer would post a loss of $0.01 per share when it actually produced a loss of $0.03, delivering a surprise of -200%.Over the last four quarters, the company has ...

OrganiGram (NasdaqGS:OGI) Q4 2025 Earnings Call December 16, 2025 08:00 AM ET Company ParticipantsGreg Guyatt - CFOMax Schwartz - Director of Investor RelationsAaron Grey - Managing Director and Head of Consumer ResearchBrenna Cunnington - Equity Research AssociatePeter Amirault - Executive ChairTim Emberg - President of Organigram CanadaOperatorGood morning. My name is Tiffany, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Organigram Global Fourth Quarter Fis ...

Financial Data and Key Metrics Changes - In Q4, net revenue increased 79% to CAD 80.1 million from CAD 44.7 million in the same prior year period [15] - Full-year fiscal 2025 net revenue increased 62% to CAD 259.2 million from CAD 159.8 million in the prior year [15] - Adjusted gross profit for Q4 increased 85% to CAD 30.6 million versus CAD 16.5 million in Q4 last year [16] - Adjusted EBITDA set a company record in fiscal 2025, with Q4 adjusted EBITDA of CAD 9.8 million, an increase of 72% sequentially and 69% year-over-year [20] - The net loss for Q4 was CAD 38 million, compared to a net loss of CAD 5.4 million in the same prior year period [22] Business Line Data and Key Metrics Changes - The acquisition of Motif Labs contributed significantly to growth without market share dilution [4] - The company achieved record international sales of CAD 26.3 million in fiscal 2025, a 171% increase versus the prior year [10] - Adjusted gross margin in Q4 rose by 400 basis points over Q3 to 38% [17] Market Data and Key Metrics Changes - Organigram holds the number one market position in Canada with 11.9% market share in fiscal 2025 [6] - The company ranked first in Ontario, British Columbia, and Alberta, and fourth in Quebec [7] - Market share in New Brunswick reached 34.2%, Newfoundland 23.7%, Saskatchewan 14.9%, and Nova Scotia 12.2% [7] Company Strategy and Development Direction - The company aims to increase the margin profile of its domestic product mix while optimizing operational footprint for capacity and throughput [9] - Plans to launch new products, including coated infused pre-rolls and beverages, to meet evolving consumer needs [9] - The focus on international expansion includes launching branded vapes and gummies in Australia [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth supported by a stronger platform and expanding international opportunities [26] - The company anticipates strong net revenue growth exceeding CAD 300 million in fiscal 2026 [24] - Management is monitoring U.S. regulatory changes that could impact the hemp-derived THC market but does not expect a material adverse economic impact [12] Other Important Information - The company received a CAD 2 million grant from Opportunities New Brunswick to support facility enhancements [6] - The Jupiter Fund currently has CAD 59 million available for deployment to leverage opportunities in markets outside of Canada [13] - The company is awaiting a determination on its EU-GMP application submitted in October 2025 [12] Q&A Session Summary Question: International growth expectations and supply-demand dynamics - Management indicated that they are starting to realize increased capacity and are well-positioned for fiscal 2026, particularly in Germany [32] Question: Gross margin expectations for fiscal 2026 - Management expects continued improvement in gross margin driven by operational improvements and synergies from the Motif acquisition [36] Question: Contribution of Motif synergies versus cultivation improvements to margin improvement - Management stated that the majority of margin improvement will come from operational improvements in cultivation rather than solely from Motif synergies [46] Question: Capital expenditure plans for the next year - Management plans to keep capital expenditures modest for fiscal 2026, expecting to spend less than CAD 10 million [47]

Investor Presentation September 30, 2025 CAUTIONARY STATEMENT This document is current as of September 30, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be reli ...

2 TORONTO--(BUSINESS WIRE)--Organigram Global Inc (NASDAQ: OGI) (TSX: OGI), (the "Company†or "Organigram†), Canada's #1 recreational cannabis company by market share, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 ("Q4 Fiscal 2025†or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS FISCAL 2025 FINANCIAL HIGHLIGHTS FISCAL 2025 COMPANY HIGHLIGHTS 2 "Fiscal ...

Group 1: Canadian Tech Sector - Celestica Inc. shares fell 12.92% due to "AI skepticism," impacting the overall index negatively [1] Group 2: Canadian Cannabis Companies - Tilray Brands Inc. shares increased by 44.35%, Canopy Growth Corp. shares rose by 52.87%, Aurora Cannabis Inc. shares were up 19.04%, and Organigram Global Inc. shares increased by 16.81% following reports of potential easing of federal restrictions on cannabis by U.S. President Donald Trump [2] - The aggressive legalization in the U.S. could revitalize Canadian cannabis stocks, which had previously seen significant declines [2] Group 3: Canadian Economic Indicators - Investors are anticipating November inflation data, with a consensus forecast of 2.3% headline inflation, which will provide insights into the Canadian economy's health [3] - The Bank of Canada policy rate is currently at 2.25% [3] Group 4: U.S. Market Performance - Broadcom's shares dropped 11.4% despite reporting stronger-than-expected profits, contributing to market concerns about the AI sector [4] - Oracle's shares fell nearly 11% after reporting better-than-expected profits, raising fears about high valuations in the AI market [5] - The S&P 500 index was notably affected by declines in Broadcom and Nvidia, with Oracle's results causing disappointment among investors [5] Group 5: Market Indices and Commodities - The Dow Jones industrial average decreased by 245.96 points, the S&P 500 index fell by 73.59 points, and the Nasdaq composite dropped by 398.69 points [6] - The Canadian dollar traded at 72.63 cents US, and crude oil prices fell by 16 cents to US$57.44 per barrel, while gold prices increased by US$15.30 to US$4,328.30 per ounce [6]

The stock prices of major cannabis companies like Tilray Brands (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC) skyrocketed 34.88% and 27.46%, respectively, in premarket trading on Friday, following reports of President Donald Trump‘s plans to relax federal regulations on marijuana. Meanwhile, Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19% and Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) rose 12% and 34.7% respectively. Reclassification Of Cannabis ...